Phase 2 N=8 Treatment

Ustekinumab (STELARA) for the Treatment of Active Sight-Threatening Uveitis (STAR Study)

Uveitis

Bottom Line

View on ClinicalTrials.gov: NCT02911116 ↗

Enrolled (actual)

Serious AEs

0.0%

Results posted

Mar 2021

Primary outcome: Primary: Number of Participants Experiencing a Treatment Response by Week 16 — 4; 2 Participants

Study Design & Population

Study type: Interventional
Phase: Phase 2
Interventions: Ustekinumab (Drug)
Age: Adult, Older Adult · 18+ yrs
Sex: All
Sponsor: National Eye Institute (NEI)
Primary completion: Mar 2020

Outcome Measures

Outcome	Result	p-value
PRIMARY Number of Participants Experiencing a Treatment Response by Week 16	4; 2	—
SECONDARY Mean Change in Visual Acuity in the Right Eye at All Follow-up Visits Compared to Baseline	-1; -1; 1; 1; 2; 0	—
SECONDARY Mean Change in Visual Acuity in the Left Eye at All Follow-up Visits Compared to Baseline	-2; 1; 4; 1; 4; 1	—
SECONDARY Median Change in Visual Acuity in the Right Eye at All Follow-up Visits Compared to Baseline	-1; -1; 2; 1; 3; 0	—
SECONDARY Median Change in Visual Acuity in the Left Eye at All Follow-up Visits Compared to Baseline	-2; 1; 2; 1; 3; 1	—
SECONDARY Number of Participants Who Experience a Recurrence of Uveitis at All Follow-up Visits	0; 0; 0; 0; 0; 0	—
SECONDARY Mean Number of Days Until First Recurrence	118	—
SECONDARY Median Number of Days Until First Recurrence	118	—
SECONDARY Presence or Extent of Macular Edema as Determined by Optical Coherence Tomography (OCT) in the Right Eye at All Follow-up Visits	2; 0; 2; 2; 2; 0	—
SECONDARY Presence or Extent of Macular Edema as Determined by Optical Coherence Tomography (OCT) in the Left Eye at All Follow-up Visits	0; 0; 3; 2; 1; 0	—
SECONDARY Presence or Extent of Macular Edema as Determined by Fluorescein Angiogram (FA) in the Right Eye at All Follow-up Visits	2; 0; 4; 0; 0; 2	—
SECONDARY Presence or Extent of Macular Edema as Determined by Fluorescein Angiogram (FA) in the Left Eye at All Follow-up Visits	1; 1; 2; 0; 2; 2	—
SECONDARY Amount of Retino-vascular Leakage as Measured by Fluorescein Angiogram (FA) in the Right Eye at All Follow-up Visits	0; 0; 0; 0; 1; 0	—
SECONDARY Amount of Retino-vascular Leakage as Measured by Fluorescein Angiogram (FA) in the Left Eye at All Follow-up Visits	0; 0; 0; 0; 1; 0	—
SECONDARY Changes in Central Retinal Thickness as Measured by Optical Coherence Tomography (OCT) in the Right Eye at All Follow-up Visits Compared to Baseline	8; -2; -49; -6; -11; 6	—
SECONDARY Changes in Central Retinal Thickness as Measured by Optical Coherence Tomography (OCT) in the Left Eye at All Follow-up Visits Compared to Baseline	-13; 1; 17; -1; 54; 2	—
SECONDARY Length of Time to Quiescence in the Right Eye	24; 38	—
SECONDARY Length of Time to Quiescence in the Left Eye	38; 38	—
SECONDARY Ability to Taper Concomitant Immunosuppressive Medications	1; 0	—

Summary

Background: Uveitis is an inflammation of the eye that can cause vision loss. It is treated with medications and sometimes surgery. However, in many people, treatment does not always prevent loss of vision. A new medication, ustekinumab, reduces inflammation in patients with other inflammatory diseases. Therefore, it might be helpful in treatment of uveitis. Objective: To see if ustekinumab is safe and can help people with uveitis. Eligibility: People ages 18 and older with uveitis Design: Participants will be screened with: Medical and eye disease history Physical exam Eye exam: The pupil is dilated with eye drops. A machine scans the back of the eye. Pictures are taken of the inside of the eye. Blood and urine tests Tuberculosis test Participants will have 6 clinic visits over 28 weeks. Visits lasts 2-3 hours and include: * Medical and eye disease history * Physical and eye exams * Blood and urine tests * Fluorescein angiography: A needle guides a thin plastic tube into an arm vein. A dye is injected into the tube. The dye travels through the veins up to the blood vessels in the eyes. A camera takes pictures of the dye as it flows through the blood vessels in the eyes. * Cohort 1 - Ustekinumab injections at Weeks 0, 4, and 8: The injection is under the skin of the upper arm, leg, or abdomen. Participants will have their uveitis monitored and receive standard uveitis care during the study. * Cohort 2 - Ustekinumab injections via intravenous (IV) injection at first visit, followed by a single 90 mg injection of ustekinumab under the skin of the upper arm, leg or abdomen. For the IV injection a needle will be used to guide a thin plastic tube (catheter) into one of the arm veins. The needle will be removed, leaving only the catheter in the vein.

Eligibility Criteria

-INCLUSION CRITERIA:

Participant has the ability to understand and sign the informed consent document.
Participant is 18 years of age or older.
Participant has negative purified protein derivative (PPD) or quantiferon testing done within three months prior to enrollment or had latent tuberculosis (TB) but has completed prophylactic anti-TB treatment.
Participant has active intermediate uveitis, posterior uveitis or panuveitis in at least one eye requiring systemic therapy. Active disease is defined as:
+1 or more vitreous haze (according to Standardization of Uveitis Nomenclature (SUN) criteria) AND/OR
Active chorioretinitis or leakage on Fluorescein angiography (FA)(that is in more than one quadrant) that requires treatment.
Participant has visual acuity in at least one eye of 20/400 or better.
Participant is willing and able to comply with the study procedures.
Female participants of childbearing potential must not be pregnant or breast-feeding, have a negative pregnancy test at screening and must be willing to undergo pregnancy testing throughout the study.
Both female participants of childbearing potential and male participants able to father a child must have (or have a partner who has) had a hysterectomy or vasectomy, be completely abstinent from intercourse or must agree to practice two effective methods of contraception throughout the course of the study and for six weeks after the last investigational product injection. Acceptable methods of contraception for this study include:
hormonal contraception (i.e., birth control pills, injected hormones, dermal patch or vaginal ring),
intrauterine device,
barrier methods (diaphragm, condom) with spermicide, or
surgical sterilization (tubal ligation).

EXCLUSION CRITERIA

Participant has a significant active infection (an infection requiring treatment as determined by the medical team), including active tuberculosis or human immunodeficiency virus (HIV).
Participant received a live vaccination within the past six weeks.
Participant is expected to receive a live vaccination at any time during the study.
Participant received the Bacillus Calmette-Guerin (BCG) vaccine within the past year.
Participant is expected to receive the BCG vaccine at any time during the study or up to one year after discontinuing ustekinumab.
Participant has a history of cancer (other than a non-melanoma skin cancer) diagnosed within the past five years.
Participant has received intraocular (or periocular) steroid or anti-vascular endothelial growth factor (VEGF) injections within the last six weeks.
Participant received rituximab within the last six months or another biologic agent (e.g., infliximab, daclizumab, adalimumab) within the last two months.
Participant has received alkylating agents (e.g., cyclophosphamide, chlorambucil) within the last nine months.
Participant has a known hypersensitivity to ustekinumab or any of its components.

View full record on ClinicalTrials.gov →

Data sourced from ClinicalTrials.gov (NCT02911116). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.